OPPI AGM: Questions over price threshold for patent working in India
This article was originally published in Scrip
The annual general meeting of the Organisation of Pharmaceutical Producers of India (OPPI) continues to provide food for thought. Last year it was GlaxoSmithKline's Andrew Witty posing tough questions on industry R&D returns. This year a senior government leader, Dilsher Singh Kalha, secretary of India's department of pharmaceuticals touched on potentially tricky areas for government, issues stemming from compulsory licensing and pricing.